WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
Position in AKBA — Akebia Therapeutics, Inc.
CIK 1632972
PLYMOUTH, MN
Position in AKBA
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$128,220
+$102,180 QoQ
Shares Held
112,474
+500.4% QoQ
Ownership
0.041%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#9
of 53 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 3%
Shared 0%
None 97%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026WEALTH ENHANCEMENT ADVISORY SERVICES, LLC holds $45,863,285 across 32 Drug Manufacturers - Specialty & Generic names. AKBA ranks #26 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
71,595 | $12,066,621 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
16,933 | $9,174,807 | |
| 3 | ZTS |
Zoetis Inc.
|
83,719 | $6,016,047 | |
| 4 | VTRS |
Viatris Inc
|
362,617 | $5,758,357 | |
| 5 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
20,499 | $1,310,911 | |
| 6 | AMRX |
Amneal Pharmaceuticals, Inc.
|
59,123 | $1,023,419 | |
| 7 | IRWD |
Ironwood Pharmaceuticals Inc
|
219,445 | $923,863 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
7,760 | $860,894 |
All Filings in AKBA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $128,220 | 112,474 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $26,040 | 18,734 | Shares | Sole | 2026-04-08 | |
| 2025-09-30 | $44,296 | 16,226 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $58,909 | 16,184 | Shares | Sole | 2025-07-10 | |
| No filing history on record for this holder in this stock. | ||||||